Physician profile
Guy L Lund
NPI 1700859279
$420.15
in general payments reported to CMS, 2019-2025
8 companies · $64.17 in 2025
The $64.17 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $22.17 · 2023: $2.66 · 2024: $46.11 · 2025: $64.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.37 · Education: $17.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.37 |
| Education | $17.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $220.86 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $49.86 | 2019 | |
| Eurofins Viracor, LLC | $42.23 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $27.89 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.12 | 2025 | Livtencity |
| Baxter Healthcare | $23.30 | 2024 | Renal - Acute |
| Travere Therapeutics, INC. | $17.57 | 2023-2025 | Filspari |
| E.R. Squibb & Sons, L.L.C. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Lund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.